Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study. Park K, Sabari JK, Haura EB, Shu CA, et al. Lung Cancer 2023;178:166-171.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Park K, Sabari JK, Haura EB, Shu CA, et al. Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study. Lung Cancer 2023;178:166-171.
PMID: 36868177